T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

PURPOSE: Therapies with novel mechanisms of action are needed for multiple myeloma (MM). T cells can be genetically modified to express chimeric antigen receptors (CARs), which are artificial proteins that target T cells to antigens. B-cell maturation antigen (BCMA) is expressed by normal and malign...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Brudno, Jennifer N., Maric, Irina, Hartman, Steven D., Rose, Jeremy J., Wang, Michael, Lam, Norris, Stetler-Stevenson, Maryalice, Salem, Dalia, Yuan, Constance, Pavletic, Steven, Kanakry, Jennifer A., Ali, Syed Abbas, Mikkilineni, Lekha, Feldman, Steven A., Stroncek, David F., Hansen, Brenna G., Lawrence, Judith, Patel, Rashmika, Hakim, Frances, Gress, Ronald E., Kochenderfer, James N.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2018
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6067798/
https://ncbi.nlm.nih.gov/pubmed/29812997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2018.77.8084
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi